A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Summary

This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.

Timeline

Start

2020-01-07

Primary completion

2023-03-31

Completion

2023-03-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor business decision”

Drugs

Indications